June 02, 2008 - C2N Diagnostics announced the availability of its first commercial assay and research service for the measurement of neurally-derived biomolecules in vivo. The SILK-Aß™ assay refers to the use of stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or metabolism, of amyloid-beta. Amyloid-beta is a small peptide implicated as a key mediator of Alzheimer’s disease. Developed in the halls of the Washington University School of Medicine by Drs. Randall Bateman and David Holtzman, the proprietary technology behind C2N’s SILK-Aß™ assay received recognition by Scientific American as one of the top 50 scientific advancements of 2006. Dr. Bateman is an Assistant Professor within the Department of Neurology and recipient of several distinguished awards for his innovative research that served the basis for C2N’s platform technology. Dr. David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chair of Neurology and Developmental Biology, and past recipient of the Potamkin prize and MetLife award for Alzheimer’s research... C2N Diagnostics' Press Release -
